 |
|
The future of schizophrenia
September 14, 2009Press conference at the 22nd Congress of the European College of Neuropsychopharmacology, Sept. 14, 2009, Istanbul, Turkey
Schizophrenia is a major public health problem. Affecting almost 1% of the world's population, it takes an enormous economic and social toll in addition to the distress, dysfunction, disability and mortality for those afflicted with this disease. Elements of the disease are present from birth, other aspects emerge during developmental years, and the illness becomes fully expressed in early adulthood with long-lasting implications for most patients.
Schizophrenia, which is seen as the paradigmatic psychiatric illness, presents different symptoms in multiple domains, whereby positive and negative phenomena can be separated (Falkai et al., 2005): Positive (psychotic) symptoms in a broader sense include delusions or delusional ideation, hallucinations, disturbance of association, catatonic symptoms, agitations as well as feelings of alien influence and suspiciousness. Negative symptoms include restricted range and intensity of emotional expression, limited thought and speech productivity, social withdrawal, and reduced initiation of goal-directed behaviour. These negative components are typically characterised as affective flattening, alogia, diminished drive, anhedonia and avolition. Furthermore, schizophrenia is associated with cognitive impairment, disorganised speech and behaviour, as well as poor attention. The primary advance in pharmacological treatment of schizophrenia was in 1952 with the introduction of dopamine antagonist antipsychotic drugs.
Paradigm shift in schizophrenia research: from single-disease entity to the paradigm of multiple domains
A century of work has been based on designs that conceptualise schizophrenia as a single disease entity, despite recognition that schizophrenia must have scientific status of a syndrome in the absence of proof of a single disease process (Carpenter et al., 1999). The implications are profound. Research based on the presumption that a single disease is present has produced weak findings that frequently fail confirmation in replication studies. The heterogeneity of patients receiving this diagnosis is substantial. Causal and neuropathological findings valid for some patients will not be found in others. Illness manifestations vary substantially between patients, and symptomatic components of illness are only weakly related to each other within individuals.
Efforts in Europe during the mid-20th Century to reduce this heterogeneity by separating 'true' or nuclear schizophrenia from other psychotic disorders became the international standard with DSM-III (Diagnostic and Statistic Manual of Mental Disorders) in 1979. The criteria for diagnosing schizophrenia had changed radically from the original Kraepelian concept of avolition combined with dissociative pathology (Kraepelin, 1896). This was replaced by reality distortion pathology with hallucinations and delusions being prominent.
Rather than a more homogeneous disease entity being defined by nuclear schizophrenia, a syndrome with substantial heterogeneity was found. Separate domains of pathology have been defined, each with its own life history and only loosely linked with the other domains (Carpenter, 2004). First six, then three domains were viewed as critical: positive psychotic symptoms, negative symptoms, and pathology observed in the interpersonal context. A paradigm shift was proposed, moving the focus of aetiological, pathophysiological and therapeutic study away from schizophrenia as a disease entity onto specific domains of pathology (Strauss et al., 1974). This indicated a shift in schizophrenia research away from the syndrome level toward study designs that aimed to identify more homogenous entities (Carpenter et al., 1999).
New evaluation for anti-schizophrenia drug therapies
In recent years, schizophrenia research has progressed in two major directions:
* First, it was determined if a disease entity within the schizophrenia syndrome could be identified. The presence or absence of negative symptoms in persons with the diagnosis of schizophrenia was ascertained and two subgroups were contrasted. The term 'deficit schizophrenia' was introduced to refer to negative symptoms that are direct manifestations of schizophrenia, not negative symptom ratings that can occur for a variety of reasons in people with schizophrenia but are not caused by schizophrenia itself. The group with primary negative symptoms, the 'deficit schizophrenia' subgroup, represented about 25% of the cases. Deficit and non-deficit subgroups could be distinguished with regard to clinical manifestations, cognitive impairment, therapeutic response, neuropathology, and aetiological risk factors. Thus, 'deficit schizophrenia' appears to be a disease entity distinguished from other forms of schizophrenia (Kirkpatrick et al., 2001; Arango et al., 2004).
* Second, the focus was put on the domains of pathology in their own right, rather than as a method for identifying a subgroup. This work has been most influential in the evaluation of drug therapies. Drugs approved for the treatment of schizophrenia have shown efficacy for psychosis per se, but not for critical aspects which determine long-term morbidity: here we find impaired cognition and negative symptoms highly associated with poor functional outcomes. Impaired cognition, with an estimated reduction in IQ of 5󈝶 points, starts relatively early in life and is probably in place by the time people begin to manifest psychosis. The aetiology and treatment of cognitive and negative symptoms of schizophrenia must be considered as individual domains separate from psychosis. Since these two pathology domains are not addressed by current anti-schizophrenia drugs, new mechanisms of drug action appear to be required (Arango et al., 2004).
Clinical implications
* One clinical implication will be addressed as the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) is developed. In addition to diagnostic categories at the syndrome level, domains of pathology will be addressed as essential to the evaluation of individuals and to identifying pathology domains to be addressed therapeutically. A parallel system of diagnostic categories and psychopathological dimensions will shift attention to each individual's specific areas of dysfunction without losing the value of syndrome categories.
* Regulatory agencies will accept domains of pathology as potential indications for drug therapy. Consensus on clinical trial designs - necessary to establish efficacy for impaired cognition or negative symptoms in schizophrenia - has been established, at least for the US Food and Drug Administration (FDA). This shifts drugs discovery in schizophrenia from producing dopamine antagonists for psychosis to novel discoveries for other key domains (apart from dopamine antagonism).
* Drugs with efficacy in impaired cognition and negative symptoms may have application across a number of disease classes. As these pathologies are observed prior to psychosis, it will raise the possibility of very early intervention and secondary prevention (Carpenter & Koenig, 2008).
* Furthermore, this shift in paradigm will influence virtually every aspect of schizophrenia research. Genetic studies, for example, will shift from the genetics of schizophrenia as a syndrome to the genetics of pathological domains. This may help clarify the apparent genetic overlap between major illness syndromes. It may be that persons with depression and psychosis share genetic vulnerability for depression with persons who have depression without psychosis. Similarly, mood disordered patients with psychosis may share vulnerability genes for psychosis with persons with schizophrenia. Finally, pathophysiology of cognitive impairment is likely to be shared among impaired individuals in several syndromes rather than being unique to each.
Conclusion
Rather than being a homogeneous disease entity, schizophrenia is characterised by separate domains of pathology, which are only loosely linked with each other.
The loss of precious human experiences and the association with poor long-term functional outcome justifies a focused and dedicated effort to discover the causes and treatments of the 'deficit syndrome' as a distinctive feature of schizophrenia.
In future schizophrenia research, the focus of therapeutic study will move away from schizophrenia as a disease entity onto specific domains of pathology, promoting the development of targeted drug therapies. To understand genetic causation, genetic studies will shift from the genetics of schizophrenia as a syndrome to the genetics of pathological domains.
As a consequence, drugs discovery in schizophrenia redeploys interests from producing dopamine antagonists for psychosis to novel discoveries targeting with new molecular targets and therapeutic profile.
As certain schizophrenia pathologies such as impaired cognition and negative symptoms are observed prior to psychosis, drugs with efficacy in these domains will raise the possibility of very early intervention and secondary prevention. This may substantially improve the quality of life for patients in the near future, and prepare the field to address recovery, cure and prevention.
###
References
1. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT Jr. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004;19:21-26
2. Carpenter WT Jr. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry 1999;46:352-360
3. Carpenter WT Jr. Clinical constructs and therapeutic discovery. Schizophr Res 2004;72:69-73
4. Carpenter WT Jr. The schizophrenia paradigm: A hundred-year challenge. The Journal of Nervous and Mental Disease 2006;194:639-643
5. Carpenter WT Jr, Koenig JI. The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. Neuropsychopharmacol 2008;33:2061-2079
6. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatr 2005;6:132-191
7. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatr 2001;58:165-171
8. Kraepelin E. Lehrbuch der Psychiatrie. 5th edition Barth, Leipzig, 1896
9. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974;11:61-69
European College of Neuropsychopharmacology
Paradigm shift in schizophrenia research: from single-disease entity to the paradigm of multiple domains
A century of work has been based on designs that conceptualise schizophrenia as a single disease entity, despite recognition that schizophrenia must have scientific status of a syndrome in the absence of proof of a single disease process (Carpenter et al., 1999). The implications are profound. Research based on the presumption that a single disease is present has produced weak findings that frequently fail confirmation in replication studies. The heterogeneity of patients receiving this diagnosis is substantial. Causal and neuropathological findings valid for some patients will not be found in others. Illness manifestations vary substantially between patients, and symptomatic components of illness are only weakly related to each other within individuals.
Efforts in Europe during the mid-20th Century to reduce this heterogeneity by separating 'true' or nuclear schizophrenia from other psychotic disorders became the international standard with DSM-III (Diagnostic and Statistic Manual of Mental Disorders) in 1979. The criteria for diagnosing schizophrenia had changed radically from the original Kraepelian concept of avolition combined with dissociative pathology (Kraepelin, 1896). This was replaced by reality distortion pathology with hallucinations and delusions being prominent.
Rather than a more homogeneous disease entity being defined by nuclear schizophrenia, a syndrome with substantial heterogeneity was found. Separate domains of pathology have been defined, each with its own life history and only loosely linked with the other domains (Carpenter, 2004). First six, then three domains were viewed as critical: positive psychotic symptoms, negative symptoms, and pathology observed in the interpersonal context. A paradigm shift was proposed, moving the focus of aetiological, pathophysiological and therapeutic study away from schizophrenia as a disease entity onto specific domains of pathology (Strauss et al., 1974). This indicated a shift in schizophrenia research away from the syndrome level toward study designs that aimed to identify more homogenous entities (Carpenter et al., 1999).
New evaluation for anti-schizophrenia drug therapies
In recent years, schizophrenia research has progressed in two major directions:
* First, it was determined if a disease entity within the schizophrenia syndrome could be identified. The presence or absence of negative symptoms in persons with the diagnosis of schizophrenia was ascertained and two subgroups were contrasted. The term 'deficit schizophrenia' was introduced to refer to negative symptoms that are direct manifestations of schizophrenia, not negative symptom ratings that can occur for a variety of reasons in people with schizophrenia but are not caused by schizophrenia itself. The group with primary negative symptoms, the 'deficit schizophrenia' subgroup, represented about 25% of the cases. Deficit and non-deficit subgroups could be distinguished with regard to clinical manifestations, cognitive impairment, therapeutic response, neuropathology, and aetiological risk factors. Thus, 'deficit schizophrenia' appears to be a disease entity distinguished from other forms of schizophrenia (Kirkpatrick et al., 2001; Arango et al., 2004).
* Second, the focus was put on the domains of pathology in their own right, rather than as a method for identifying a subgroup. This work has been most influential in the evaluation of drug therapies. Drugs approved for the treatment of schizophrenia have shown efficacy for psychosis per se, but not for critical aspects which determine long-term morbidity: here we find impaired cognition and negative symptoms highly associated with poor functional outcomes. Impaired cognition, with an estimated reduction in IQ of 5󈝶 points, starts relatively early in life and is probably in place by the time people begin to manifest psychosis. The aetiology and treatment of cognitive and negative symptoms of schizophrenia must be considered as individual domains separate from psychosis. Since these two pathology domains are not addressed by current anti-schizophrenia drugs, new mechanisms of drug action appear to be required (Arango et al., 2004).
Clinical implications
* One clinical implication will be addressed as the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) is developed. In addition to diagnostic categories at the syndrome level, domains of pathology will be addressed as essential to the evaluation of individuals and to identifying pathology domains to be addressed therapeutically. A parallel system of diagnostic categories and psychopathological dimensions will shift attention to each individual's specific areas of dysfunction without losing the value of syndrome categories.
* Regulatory agencies will accept domains of pathology as potential indications for drug therapy. Consensus on clinical trial designs - necessary to establish efficacy for impaired cognition or negative symptoms in schizophrenia - has been established, at least for the US Food and Drug Administration (FDA). This shifts drugs discovery in schizophrenia from producing dopamine antagonists for psychosis to novel discoveries for other key domains (apart from dopamine antagonism).
* Drugs with efficacy in impaired cognition and negative symptoms may have application across a number of disease classes. As these pathologies are observed prior to psychosis, it will raise the possibility of very early intervention and secondary prevention (Carpenter & Koenig, 2008).
* Furthermore, this shift in paradigm will influence virtually every aspect of schizophrenia research. Genetic studies, for example, will shift from the genetics of schizophrenia as a syndrome to the genetics of pathological domains. This may help clarify the apparent genetic overlap between major illness syndromes. It may be that persons with depression and psychosis share genetic vulnerability for depression with persons who have depression without psychosis. Similarly, mood disordered patients with psychosis may share vulnerability genes for psychosis with persons with schizophrenia. Finally, pathophysiology of cognitive impairment is likely to be shared among impaired individuals in several syndromes rather than being unique to each.
Conclusion
Rather than being a homogeneous disease entity, schizophrenia is characterised by separate domains of pathology, which are only loosely linked with each other.
The loss of precious human experiences and the association with poor long-term functional outcome justifies a focused and dedicated effort to discover the causes and treatments of the 'deficit syndrome' as a distinctive feature of schizophrenia.
In future schizophrenia research, the focus of therapeutic study will move away from schizophrenia as a disease entity onto specific domains of pathology, promoting the development of targeted drug therapies. To understand genetic causation, genetic studies will shift from the genetics of schizophrenia as a syndrome to the genetics of pathological domains.
As a consequence, drugs discovery in schizophrenia redeploys interests from producing dopamine antagonists for psychosis to novel discoveries targeting with new molecular targets and therapeutic profile.
As certain schizophrenia pathologies such as impaired cognition and negative symptoms are observed prior to psychosis, drugs with efficacy in these domains will raise the possibility of very early intervention and secondary prevention. This may substantially improve the quality of life for patients in the near future, and prepare the field to address recovery, cure and prevention.
###
References
1. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT Jr. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004;19:21-26
2. Carpenter WT Jr. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry 1999;46:352-360
3. Carpenter WT Jr. Clinical constructs and therapeutic discovery. Schizophr Res 2004;72:69-73
4. Carpenter WT Jr. The schizophrenia paradigm: A hundred-year challenge. The Journal of Nervous and Mental Disease 2006;194:639-643
5. Carpenter WT Jr, Koenig JI. The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. Neuropsychopharmacol 2008;33:2061-2079
6. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatr 2005;6:132-191
7. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatr 2001;58:165-171
8. Kraepelin E. Lehrbuch der Psychiatrie. 5th edition Barth, Leipzig, 1896
9. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974;11:61-69
European College of Neuropsychopharmacology
Schizophrenia Current Events and Schizophrenia News RSSSchizophrenia gene's role may be broader, more potent, than thought
UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia.
Full recovery now possible for an 'untreatable' mental illness
Patients coping with the chaos and misery of Borderline Personality Disorder now have reason for strong confidence in making major life changes through a new treatment, Schema Therapy.
Immune system activated in schizophrenia
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.
Why can't chimps speak?
If humans are genetically related to chimps, why did our brains develop the innate ability for language and speech while theirs did not?
Developmental delay could stem from nicotinic receptor deletion
The loss of a gene through deletion of genetic material on chromosome 15 is associated with significant abnormalities in learning and behavior, said a consortium of researchers led by Baylor College of Medicine (www.bcm.edu) in a report that appears online today in the journal Nature Genetics.
Fighting Sleep, Penn Researchers Reverse the Cognitive Impairment Caused By Sleep Deprivation
A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.
Testicular tumors may explain why some diseases are more common in children of older fathers
A rare form of testicular tumour has provided scientists with new insights into how genetic changes (mutations) arise in our children.
CSHL-led team discovers rare mutation dramatically increasing schizophrenia risk
An international team of researchers led by geneticist Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL), has identified a mutation on human chromosome 16 that substantially increases risk for schizophrenia.
Faulty 'wiring' in the brain triggers onset of schizophrenia
A new study by researchers at the Institute of Psychiatry (IoP), King's College London has discovered abnormalities in the white matter of the brain that seem to be critical for the timing of schizophrenia.
General anesthetics lead to learning disabilities in animal models
Studies by researchers at Wake Forest University School of Medicine have shown that blocking the NMDA receptor in immature rats leads to profound, rapid brain injury and disruption of auditory function as the animals mature.
More Schizophrenia Current Events and Schizophrenia News Articles
 |
Surviving Schizophrenia: A Manual for Families, Patients, and Providers by E. Fuller Torrey (Author) Since its first publication in 1983, Surviving Schizophrenia has become the standard reference book on the disease and has helped thousands of patients, their families and mental health professionals. In clear language, this much–praised and important book describes the nature, causes, symptoms, treatment and course of schizophrenia and also explores living with it from both the patient and the family's point of view. This new, completely updated fifth edition includes the latest research findings on what causes the disease as well as information about the newest drugs for treatment and answers to the questions most often asked by families, consumers and providers. |
 |
Schizophrenia Revealed: From Neurons to Social Interactions by Michael Foster Green (Author) A modern view of schizophrenia based on neuroscience that goes far beyond the symptoms of the illness. "Green has lifted the bar in this realm of explanatory neuroscience-based psychiatry. If you wish to read an enjoyable and instructive primer on what we know about schizophrenia at the beginning of the 21st century, you could do no better than to choose Schizophrenia Revealed." —New England Journal of Medicine |
 |
The Quiet Room: A Journey Out of the Torment of Madness by Lori Schiller (Author), Amanda Bennett (Author) Schiller's gripping, heart-rending and ultimately triumphant story of her journey into madness and back to reality is told through the voices of Lori and her family, friends and doctor, and captures a rare, astoundingly vivid view into the inner life of a schizophrenic. "A stunning story of courage, persistence, and hope."--Publishers Weekly. |
 |
ABC News 20/20 Schizophrenia It's all in their minds: visions, voices, taunting, never ending, driving them crazy or worse. It's hard to imagine, but now, an amazing device lets you feel their pain. The technology lets you go inside the mind of a schizophrenic. See what they see. Hear what they hear. Using the technique of virtual reality, Janssen Pharmaceuticals has developed a device to stimulate the visual and auditory hallucinations of a schizophrenic patient. Dr. Timothy Johnson explores the world of people struggling with the voices within. This "20/20" show contains the following additional stories: Victim's Comp Windsheilds |
 |
The Complete Family Guide to Schizophrenia: Helping Your Loved One Get the Most Out of Life by Kim T. Mueser PhD (Author), Susan Gingerich MSW (Author) Will the person you love ever get better? Chances are you've grappled with the question. With care and support from their families, people with schizophrenia can and do make vast improvements. Noted therapists Kim Mueser and Susan Gingerich deepen your understanding of the illness and cover a wide range of effective treatments. Based on decades of research and experience, they offer pragmatic suggestions for dealing with depression, psychosis, and other symptoms. They show you how to prioritize needs, resolve everyday problems, and encourage your loved one to set life goals. Plus, individual sections highlight special issues for parents, children, siblings, and partners. Whether you’re facing schizophrenia for the first time or you’ve dealt with its impact for years, you’ll discover... |
 |
Schizophrenia For Dummies (For Dummies (Health & Fitness)) by Jerome Levine (Author), Irene S. Levine (Author) Practical tools for leading a happy, productive life Schizophrenia is a chronic, severe, and disabling mental disorder that afflicts one percent of the population, an estimated 2.5 million people in America alone. The firsthand advice in this reassuring guide will empower the families and caregivers of schizophrenia patients to take charge, offering expert advice on identifying the warning signs, choosing the right health professional, understanding currently available drugs and those on the horizon (as well as their side effects), and evaluating traditional and alternative therapies. |
 |
Getting Your Life Back Together When You Have Schizophrenia by Roberta Temes (Author) |
 |
Me, Myself, and Them: A Firsthand Account of One Young Person's Experience with Schizophrenia (Adolescent Mental Health Initiative) by Kurt Snyder (Author), Raquel E. Gur M.D. (Author), Linda Wasmer Andrews (Author) During his second semester at college, Kurt Snyder became convinced that he was about to discover a fabulously important mathematical principle, spending hours lost in daydreams about numbers and symbols. In time, his thoughts took a darker turn, and he became preoccupied with the idea that cars were following him, or that strangers wanted to harm him. Kurt's mind had been hijacked by schizophrenia, a severe mental disorder that typically strikes during the late teen or young adult years. In Me, Myself, and Them, Kurt, now an adult, looks back from the vantage point of recovery and eloquently describes the debilitating changes in thoughts and perceptions that took hold of his life during his teens and twenties. As a memoir, this book is remarkable for its unvarnished look at the... |
 |
Understanding Mental Illness and Schizophrenia Part of the award winning public television series Healthy Body/Healthy Mind. Mental Illnesses are complex diseases of the brain affecting thoughts, moods, and coping ability. There are many diseases you can see, feel and understand, but there are others that aren't as easy to comprehend. Education and compassion are key. Untreated mental illness costs Americans more than 100 billion dollars each year. Fear of Mental Illness and the lack of understanding prevent millions of people from seeking much needed treatment. Meet some of these people in this program. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Recovered, Not Cured: A Journey Through Schizophrenia by Richard McLean (Author) This very personal exploration of schizophrenia explores each stage, from the early signs and reactions from friends and family to seeking help and the challenges of recovery. McLean bravely shares his paranoid delusions and offers both a verbal and a visual experience by including digital artwork he created to help objectify and control his impulses and fears. As McLean relates his experiences step by step, issues of sexuality, identity, and drug abuse are discussed, along with the overarching issues relating to mental health and the medical profession. Messages from online posters who either have suffered from mental illness or have cared for the mentally ill are included throughout, adding more perspectives to the author's personal experiences. This powerful combination of words and... |
| © 2009 BrightSurf.com |